JSPRWNCM

Jasper Therapeutics, Inc.

-16.9% · 90d

$0.02

+0.00 (+1.29%)

News

No News Yet

Press releases and SEC filings for JSPRW will appear here as they are published.

Check back later for updates

Key Data

Market Cap—

Open$0.08

Prev Close$0.02

Day Range$0.02 – $0.02

52W Range$0.02 – $0.02

Volume63,026

P/E (TTM)—

EPS$-3.84

Dividend Yield—

Beta3.20

About

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases. The company's lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, and asthma, as well as conditioning agents for stem cell transplant in patients with sickle cell disease, Fanconi anemia, and severe combined immunodeficiency. Jasper Therapeutics, Inc. was founded in 2018 and is based in Redwood City, California.

22 employees

jaspertx.com

Top Institutional Holders

As of 2025-12-31 · prior 2025-09-30

Soleus Capital Management, L.P.$366,000

200,000 sh-86.6%

GOLDMAN SACHS GROUP INC$3.2M

1,746,492 sh+6394.9%

MORGAN STANLEY$3.6M

1,969,785 sh+149.3%

CITADEL ADVISORS LLC$133,956

73,200 sh-88.8%

Velan Capital Investment Management LP$4.9M

2,668,395 sh0.0%

See all holders →

Quarterly Financials

09/25

Revenue Net Income